What is it? Why is it important?

Non-compliance addresses the non-adherence to given instruction(s).

 

Protocol non-compliance may threaten the Critical-to-Quality factors of the study, such as participant safety and rights, data quality, regulatory compliance, and the scientific validity of the study.

 

Protocol non-compliance are classified either as a:

  • Deviation: Less serious, accidental or unintentional non-compliance that does not significantly affect the study (e.g. minor timing deviation, missing signatures on the study delegation-log)
  • Violation: More serious non-compliance that may lead to the exclusion of participants from data analysis, the inability to reach study outcome / endpoint, and/or discontinuation of the study (e.g. enrolment of non-eligible participants, use of expired investigational product (IMP / IMD), deviation from correct consent procedures)

What do I need to do?

As a SP-INV,

  • Document all protocol deviations, including reasons for the deviation in a Note-to-File or a deviation log. Date and sign documents and file documents in the study TMF/ISF
  • Assess non-compliance and its potential impact on the study (e.g. study timeline, quality-process adaptations (e.g. SOP, WI), study analysis and reporting, protocol amendment, resources, budget)
  • Participants non-compliant may significantly jeopardise data quality and study outcome (e.g. unreliable medication intake). Plan procedures that support participant compliance, and plan measure to assess participant compliance during study conduct
  • In the event of persistent non-compliance at a particular study site, decide to close the site and report non-compliance to the EC, and if applicable Swissmedic

 

Define procedures on how to handle non-compliance such as to:

  • Perform a root-cause analysis of the deviation
  • Define appropriate Corrective and Preventative Actions (CAPA).
  • Train study staff on defined risk control-measures
  • Document CAPAs and plan risk reviews

Where can I get help?

Your local Research Support Centre can assist you with experienced staff regarding this topic

  • Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch

  • Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch

  • Bern, Department of Clinical Research (DCR), dcr.unibe.ch

  • Geneva, Clinical Research Center (CRC), crc.hug.ch

  • Lausanne, Clinical Research Center (CRC), chuv.ch

  • St. Gallen, Clinical Trials Unit (CTU), h-och.ch

  • Zürich, Clinical Trials Center (CTC), usz.ch

References

ICH GCP E6(R3) – see in particular guidelines

  • Glossary Definition: Compliance
  • 3.12 Noncompliance

ICH E8(R1) – see in particular

  • 3.2 Critical to Quality Factors

ISO 9001:2015 (access liable to costs) – see in particular section

  • Quality Management Systems
Abbreviations
  • CAPA – Corrective and Preventive Action
  • CTU – Clinical Trials Unit
  • EC – Ethics Committee
  • ICH – International Council for Harmonisation
  • ICH GCP – International Council for Harmonisation Good Clinical Practice
  • IMP / IMD – Investigational Medicinal Product / Investigational Medical Device
  • FOPH – Federal Office of Public Health
  • ISO – International Organization for Standardization
  • ISF – Investigator Site File
  • SOP – Standard Operating Procedures
  • SP-INV – Sponsor-Investigator
  • TMF/ISF – Trial Master File / Investigator Site File
  • WI – Working Instructions
Development ↦ Quality and Risk ↦ Quality Control ↦ Non-Compliance
Study
Basic

Provides some background knowledge and basic definitions

Basic Monitoring
Concept

Starts with a study idea

Ends after having assessed and evaluated study feasibility

Concept Statistic Methodology
Concept Drug or Device
Development

Starts with confidence that the study is feasible

Ends after having received ethics and regulatory approval

Development Drug or Device
Set-Up

Starts with ethics and regulatory approval

Ends after successful study initiation

Set-Up Ethics and Laws
Set-Up Statistic Methodology
Set-Up Quality and Risk
Set-Up Drug or Device
Conduct

Starts with participant recruitment

Ends after the last participant has completed the last study visit

Conduct Statistic Methodology
Conduct Drug or Device
Completion

Starts with last study visit completed

Ends after study publication and archiving

Completion Drug or Device
Current Path (click to copy): Development ↦ Quality and Risk ↦ Quality Control ↦ Non-Compliance